Accessibility Menu
Profound Medical logo

Profound Medical(TSX) PRN

Current PriceCA$9.57
Market CapCA$358.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-34%
5 Year-48%
1 Year+23%
1 Month+6%
Profound Medical last closing stock price
MetricPriceDate
Last closeCAD 9.862026-07-22
Profound Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.2%CAD 9.842026-07-15
1 month+5.68%CAD 9.332026-06-22
3 month+5.57%CAD 9.342026-04-23
Year to date-8.45%CAD 10.772025-12-31
1 year+23.25%CAD 8.002025-07-22
3 year-40.21%CAD 16.492023-07-21
5 year-48.21%CAD 19.042021-07-23
Since inception-34.27%CAD 15.002015-06-09

Profound Medical Financials at a Glance

Market Cap

CA$358.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.76M

Net Income (TTM)

-$38.82M

EPS (TTM)

-CA$1.73

P/E Ratio

-5.71

Dividend

CA$0.00

Beta (Volatility)

1.04 (Average)

Price

CA$9.57

Volume

805

Open

CA$9.97

Previous Close

CA$9.86

Daily Range

CA$9.57 - CA$9.97

52-Week Range

CA$5.23 - CA$12.40

Estimated Earnings Date

Aug 6, 2026

PRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Profound Medical

Profound Medical Corp. is a commercial-stage medical technology firm specializing in innovative magnetic resonance (MR) guided ablation therapies. The company focuses on addressing prostate conditions, uterine fibroids, and providing palliative pain management through its advanced medical devices.

Products and Services
  • TULSA-PRO system for prostate treatment using MRI guidance
  • Sonalleve platform for treating uterine fibroids and palliative pain
  • Comprehensive solutions for non-invasive medical therapies
Growth Outlook
  • Expansion into new markets, including the U.S. and Germany
  • Increasing demand for non-invasive treatment options in healthcare
  • Strategic partnerships to enhance product offerings and market reach
Financial Highlights
  • Recent quarterly revenue of 5.25 million, showing growth potential
  • Cash reserves of over 50 million, providing operational stability
  • Current ratio of 6.56, indicating strong liquidity position
Profound Medical Corp. operates in the medical devices industry, focusing on advanced therapeutic solutions. The TULSA-PRO system represents a significant innovation in prostate treatment, integrating seamlessly with MRI technology. The Sonalleve platform further diversifies the company's offerings, addressing both uterine fibroids and palliative care needs. The growth outlook for Profound Medical is promising, driven by an increasing demand for non-invasive medical treatments and strategic market expansions. Recent financial data indicates a solid revenue stream and a robust cash position, which can support ongoing research and development efforts. The company's strong liquidity, as evidenced by its current ratio, positions it well to navigate the evolving healthcare landscape. Overall, Profound Medical Corp. presents an intriguing opportunity for investors interested in the medical technology sector, particularly in innovative solutions that address significant healthcare challenges.
AI Generated • Jul 21, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

162

CEO

Arun S. Menawat, PhD, EMBA

Website

www.profoundmedical.com

Headquarters

Mississauga, ON L4W 5K5, CA

PRN Financials

Key Financial Metrics (TTM)

Gross Margin

71.04%

Operating Margin

-202.52%

Net Income Margin

-206.94%

Return on Equity

-78.75%

Return on Capital

-59.11%

Return on Assets

-52.81%

Earnings Yield

-17.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$358.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.34M

Volume

805

Avg. Volume

11.37K

Financials (TTM)

Gross Profit

$13.33M

Operating Income

-$37.99M

EBITDA

-$36.45M

Operating Cash Flow

-$38.32M

Capital Expenditure

-$179.08K

Free Cash Flow

-$38.50M

Cash & ST Invst.

$50.33M

Total Debt

$7.47M

Profound Medical Performance Analysis

Profound Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,697,6830.9%
20232023-12-31USD 9,716,39611.7%
20242024-12-31USD 14,631,19050.6%
20252025-12-31USD 22,493,55153.7%
Profound Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-15.6%
Q32025-09-30136.6%
Q42025-12-3116.0%
Q12026-03-31-13.5%
Profound Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.79-4.7%
20232023-12-31USD -1.800.7%
20242024-12-31USD -1.54-14.7%
20252025-12-31USD -1.9727.9%
Profound Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-44.4%
Q32025-09-3050.0%
Q42025-12-31-3.8%
Q12026-03-3129.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.25M

+100.3%

Gross Profit

$3.77M

+103.4%

Gross Margin

71.80%

N/A

Market Cap

CA$358.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.21M

N/A

Employees

162

N/A

Net Income

-$6.94M

+35.3%

EBITDA

-$7.79M

+29.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$50.33M

+8.4%

Total Debt

$7.47M

+52.9%

Accounts Receivable

$9.43M

+58.1%

Inventory

$9.01M

+32.6%

Long Term Debt

$2.89M

-37.4%

Short Term Debt

$4.57M

+618.0%

Return on Assets

-52.81%

N/A

Return on Invested Capital

-60.41%

N/A

Free Cash Flow

-$8.44M

-1.9%

Operating Cash Flow

-$8.44M

-1.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DR.TOMedical Facilities Corporation
CA$17.95+0.11%
NGEN.VNervGen Pharma Corp.
CA$5.15+3.00%
XLY.TOAuxly Cannabis Group Inc.
CA$0.19-1.35%
CRRX.TOCareRx Corporation
CA$3.35+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.88-0.28%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.16+0.05%
HBANHuntington Bancshares
$17.38-0.05%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$37.03+0.08%

Questions About PRN

What is the current price of Profound Medical?

Profound Medical is trading at CA$9.57 per share.

What is the 52-week range for Profound Medical?

Over the past 52 weeks, Profound Medical has traded between CA$5.23 and CA$12.40.

How much debt does Profound Medical have?

As of the most recent reporting period, Profound Medical reported total debt of $10.41M.

How much cash does Profound Medical have on hand?

Profound Medical reported $70.19M in cash and cash equivalents in its most recent financial results.

What is Profound Medical’s dividend yield?

Profound Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services